Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T16:34:09.337Z.
Calculation as of: 2026-10-06T16:34:09.337Z.
Quote observation: 2026-10-06T16:30:41.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 09a0ab09da9db255713b3d52bc1d4f6ff3c974c87d2899d50b33d975ee1631b8
EARNINGS YIELD
N/A
Prelude Therapeutics Incorporated
Market Cap
$214.35M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.39M
Earnings Yield
6.92%
TTM Avg
4.72%
3Y Avg
3.13%
5Y Avg
3.13%
Market Cap
$218.36M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$208.90M
Earnings Yield
N/A
TTM Avg
19.04%
3Y Avg
19.04%
5Y Avg
19.04%
Market Cap
$221.27M
Earnings Yield
N/A
TTM Avg
9.26%
3Y Avg
9.26%
5Y Avg
9.26%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $214.35M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.39M | 6.92% | 4.72% | 3.13% | 3.13% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $218.36M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $211.80M | 16.76% | 15.50% | 9.57% | 9.57% |
| Alector, Inc. (ALEC)vs › | $216.72M | N/A | 3.98% | 3.98% | 3.98% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $218.09M | N/A | N/A | N/A | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $208.90M | N/A | 19.04% | 19.04% | 19.04% |
| Sionna Therapeutics, Inc. (SION)vs › | $209.27M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $221.27M | N/A | 9.26% | 9.26% | 9.26% |
| Pro-Dex, Inc. (PDEX)vs › | $206.63M | 6.37% | 7.28% | 6.45% | 6.38% |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
